Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Payables (2016 - 2025)

Lexaria Bioscience's Payables history spans 11 years, with the latest figure at $1.4 million for Q4 2025.

  • For Q4 2025, Payables rose 429.93% year-over-year to $1.4 million; the TTM value through Nov 2025 reached $1.4 million, up 429.93%, while the annual FY2025 figure was $1.5 million, 37.19% up from the prior year.
  • Payables for Q4 2025 was $1.4 million at Lexaria Bioscience, down from $1.5 million in the prior quarter.
  • Across five years, Payables topped out at $1.8 million in Q1 2025 and bottomed at $55318.0 in Q1 2024.
  • The 5-year median for Payables is $189659.0 (2021), against an average of $524702.6.
  • The largest annual shift saw Payables crashed 87.42% in 2024 before it soared 3141.4% in 2025.
  • A 5-year view of Payables shows it stood at $189542.0 in 2021, then increased by 27.62% to $241891.0 in 2022, then plummeted by 59.09% to $98969.0 in 2023, then skyrocketed by 171.79% to $268986.0 in 2024, then soared by 429.93% to $1.4 million in 2025.
  • Per Business Quant, the three most recent readings for LEXX's Payables are $1.4 million (Q4 2025), $1.5 million (Q3 2025), and $1.5 million (Q2 2025).